- Home
- HBI vs GLPG Comparison
HBI vs GLPG Comparison
Compare HBI & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBI
- GLPG
- Stock Information
- Founded
- HBI 1901
- GLPG 1999
- Country
- HBI United States
- GLPG Belgium
- Employees
- HBI N/A
- GLPG N/A
- Industry
- HBI Clothing/Shoe/Accessory Stores
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- HBI Consumer Discretionary
- GLPG Health Care
- Exchange
- HBI Nasdaq
- GLPG Nasdaq
- Market Cap
- HBI 2.2B
- GLPG 2.1B
- IPO Year
- HBI 2006
- GLPG 2005
- Fundamental
- Price
- HBI $6.31
- GLPG $32.06
- Analyst Decision
- HBI Buy
- GLPG Sell
- Analyst Count
- HBI 4
- GLPG 4
- Target Price
- HBI $6.50
- GLPG $25.33
- AVG Volume (30 Days)
- HBI 6.8M
- GLPG 184.7K
- Earning Date
- HBI 11-06-2025
- GLPG 10-29-2025
- Dividend Yield
- HBI N/A
- GLPG N/A
- EPS Growth
- HBI N/A
- GLPG N/A
- EPS
- HBI 0.25
- GLPG N/A
- Revenue
- HBI $3,540,309,000.00
- GLPG $323,674,692.00
- Revenue This Year
- HBI $1.61
- GLPG N/A
- Revenue Next Year
- HBI N/A
- GLPG N/A
- P/E Ratio
- HBI $25.11
- GLPG N/A
- Revenue Growth
- HBI 2.95
- GLPG 5.43
- 52 Week Low
- HBI $3.96
- GLPG $22.36
- 52 Week High
- HBI $9.10
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- HBI 60.21
- GLPG 48.29
- Support Level
- HBI $6.22
- GLPG $30.88
- Resistance Level
- HBI $6.45
- GLPG $33.63
- Average True Range (ATR)
- HBI 0.14
- GLPG 0.67
- MACD
- HBI -0.07
- GLPG -0.05
- Stochastic Oscillator
- HBI 64.10
- GLPG 36.36
About HBI Hanesbrands Inc.
Hanesbrands manufactures basic and athletic apparel under brands including Hanes, Playtex, Maidenform, Bali, Berlei, and Bonds. The company sells wholesale to discount, midmarket, and department store retailers as well as direct to consumers through stores and e-commerce. Hanesbrands is vertically integrated, as it produces nearly 75% of its products in company-controlled factories in more than three dozen nations. Hanesbrands distributes products in the Americas and Asia-Pacific. The company was founded in 1901 and is based in Winston-Salem, North Carolina. Hanesbrands has agreed to be acquired by Canadian rival Gildan.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.